Immunotherapies for COVID-19: lessons learned from sepsis

Kenneth E. Remy; Scott C. Brakenridge; Bruno Francois; Thomas Daix; Clifford S. Deutschman; Guillaume Monneret; Robin Jeannet; Pierre Francois Laterre; Richard S. Hotchkiss; Lyle L. Moldawer

doi:10.1016/S2213-2600(20)30217-4

Immunotherapies for COVID-19: lessons learned from sepsis

Kenneth E. Remy, Scott C. Brakenridge, Bruno Francois, Thomas Daix, Clifford S. Deutschman, Guillaume Monneret, Robin Jeannet, Pierre Francois Laterre, Richard S. Hotchkiss, Lyle L. Moldawer

Research output: Contribution to journal › Comment/debate

111 Scopus citations

Original language	English
Pages (from-to)	946-949
Number of pages	4
Journal	The Lancet Respiratory Medicine
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/S2213-2600(20)30217-4
State	Published - Oct 2020

Access to Document

10.1016/S2213-2600(20)30217-4

Cite this

@article{15d93808b5b4468fa3e9aed757b0f8c0,

title = "Immunotherapies for COVID-19: lessons learned from sepsis",

author = "Remy, {Kenneth E.} and Brakenridge, {Scott C.} and Bruno Francois and Thomas Daix and Deutschman, {Clifford S.} and Guillaume Monneret and Robin Jeannet and Laterre, {Pierre Francois} and Hotchkiss, {Richard S.} and Moldawer, {Lyle L.}",

note = "Funding Information: SCB reports other support from Revimmune and Bristol Myers Squibb, outside of the submitted work. BF reports personal fees from Biom{\'e}rieux, Aridis, Ashai-Kasai, Polyphor, AM-Pharma, Ferring, Inotrem, Enlivex, and Transgene, outside of the submitted work. CSD reports grants from National Institute of General Medical Sciences (NIGMS), other support from Enlivex, and non-financial support from La Jolla Pharmaceuticals, outside of the submitted work. RSH is the principal investigator on a clinical trial of IL-7 in sepsis, has received reimbursement for travel and lodging expenses for a steering committee meeting, and reports grants from NIGMS. LLM reports grants from NIGMS, outside of the submitted work. KER, RJ, TD, GM, and P-FL declare no competing interests.",

year = "2020",

month = oct,

doi = "10.1016/S2213-2600(20)30217-4",

language = "English",

volume = "8",

pages = "946--949",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

number = "10",

}

TY - JOUR

T1 - Immunotherapies for COVID-19

T2 - lessons learned from sepsis

AU - Remy, Kenneth E.

AU - Brakenridge, Scott C.

AU - Francois, Bruno

AU - Daix, Thomas

AU - Deutschman, Clifford S.

AU - Monneret, Guillaume

AU - Jeannet, Robin

AU - Laterre, Pierre Francois

AU - Hotchkiss, Richard S.

AU - Moldawer, Lyle L.

N1 - Funding Information: SCB reports other support from Revimmune and Bristol Myers Squibb, outside of the submitted work. BF reports personal fees from Biomérieux, Aridis, Ashai-Kasai, Polyphor, AM-Pharma, Ferring, Inotrem, Enlivex, and Transgene, outside of the submitted work. CSD reports grants from National Institute of General Medical Sciences (NIGMS), other support from Enlivex, and non-financial support from La Jolla Pharmaceuticals, outside of the submitted work. RSH is the principal investigator on a clinical trial of IL-7 in sepsis, has received reimbursement for travel and lodging expenses for a steering committee meeting, and reports grants from NIGMS. LLM reports grants from NIGMS, outside of the submitted work. KER, RJ, TD, GM, and P-FL declare no competing interests.

PY - 2020/10

Y1 - 2020/10

UR - http://www.scopus.com/inward/record.url?scp=85084601840&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(20)30217-4

DO - 10.1016/S2213-2600(20)30217-4

M3 - Comment/debate

C2 - 32444269

AN - SCOPUS:85084601840

SN - 2213-2600

VL - 8

SP - 946

EP - 949

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 10

ER -

Immunotherapies for COVID-19: lessons learned from sepsis

Access to Document

Other files and links

Cite this